Skip to main content

Serina Therapeutics, Inc.

corporate_fare Company Profile

Serina Therapeutics, Inc.

SER·NYSE·Life Sciences·CIK 0001708599

Serina Therapeutics, Inc. is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Its proprietary POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities, including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). The POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline), engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via easy-to-administer, long-acting subcutaneous injection. The therapeutic agents in the company's small molecule product candidates are typically well-understood and marketed drugs that are effective but limited by pharmacokinetic (PK) profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood, and that POZ technology can be applied to small molecules, proteins, ADCs and other classes of molecules. The chemical attachment of water-soluble polymers, in particular polyethylene glycol (PEG), to drugs has become a valuable technique for improving the properties of pharmaceuticals and has been successfully employed in producing many FDA-approved drugs. Serina believes there is an unmet need for polymer delivery technology that addresses the limitations of PEG and other biocompatible polymers. Among the stated advantages of POZ: it is produced using inexpensive starting materials in essentially a "one pot" synthesis and is stable at room temperature, whereas PEG is comprised of repeating units of ethylene glycol and is synthesized by ring opening polymerization of ethylene oxide, a flammable, toxic, explosive and colorless gas; high quality PEG is available from only a few industrial-scale facilities and is relatively expensive, and its manufacturing process is quite dangerous and is typically not done in research laboratories and not in FDA-approved GMP manufacturing facilities.

Serina Therapeutics, Inc. (NYSE:SER) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for SER at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Recent SEC coverage for SER spans 10-Q.

Recent high-impact activity:

  • Serina Q3 10-Q: $19.4M Cash, Yet Going-Concern Doubt Persists

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$130K
Net Income
-$19.18M
Diluted EPS
-$1.91
Op. Cash Flow
-$17.95M
Free Cash Flow
-$18.01M
Operating Income
-$24.02M
Cash & Equivalents
$3.06M
Total Debt
$2.95M
Debt / Equity
-79.62×
Net Margin
-147.55×
Shares Outstanding
10.77M sh
Source: 10-K · filed 2026-03-27 · accession 0001708599-26-000022

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 46,787 shares in SER as of the October 30, 2026 settlement, a 6.7% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 48.5% of SER volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)46,787 shares as of October 30, 2026
Change vs prior period▲ 6.7%
Days to cover1.00 at avg daily volume of 58,085
Daily short volume (FINRA facilities)48.5% of 36,830 shares on November 20, 2026
5-day average short volume23.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$1.15 +2.68% today
52-week range · as of 2026-11-12 $1.14 – $4.26
Market cap
$29.76M
Volume
62.4K (1.0× avg)
3-mo avg 63.8K
Live data · 2026-11-21 06:58 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SER - Latest Insights

SER
Nov 12, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.41
Real-time Price: $1.15 info
Change: -$0.260 (-18%) info
Market Cap: $29.758M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets